KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBITDA: 2010-2025

Historic EBITDA for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$178.0 million.

  • Novavax's EBITDA fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • According to the latest figures from Q3 2025, Novavax's EBITDA is -$178.0 million, which was down 276.13% from $101.1 million recorded in Q2 2025.
  • Novavax's 5-year EBITDA high stood at $515.5 million for Q1 2025, and its period low was -$825.0 million during Q4 2021.
  • In the last 3 years, Novavax's EBITDA had a median value of -$131.1 million in 2024 and averaged -$34.3 million.
  • As far as peak fluctuations go, Novavax's EBITDA plummeted by 1,931.06% in 2021, and later soared by 455.94% in 2025.
  • Novavax's EBITDA (Quarterly) stood at -$825.0 million in 2021, then spiked by 70.44% to -$243.9 million in 2022, then climbed by 24.73% to -$183.6 million in 2023, then grew by 28.59% to -$131.1 million in 2024, then tumbled by 32.83% to -$178.0 million in 2025.
  • Its last three reported values are -$178.0 million in Q3 2025, $101.1 million for Q2 2025, and $515.5 million during Q1 2025.